124 related articles for article (PubMed ID: 30207834)
1. TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway.
Lin M; Yao Z; Zhao N; Zhang C
Cancer Biol Ther; 2019; 20(1):101-108. PubMed ID: 30207834
[TBL] [Abstract][Full Text] [Related]
2. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
4. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
6. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
[TBL] [Abstract][Full Text] [Related]
7. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Fang H; Jin J; Huang D; Yang F; Guan X
Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
[TBL] [Abstract][Full Text] [Related]
8. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
9. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
10. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Woo SM; Min KJ; Chae IG; Chun KS; Kwon TK
Mol Carcinog; 2015 Mar; 54(3):216-28. PubMed ID: 24127286
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression.
Wu W; Wang Y; Xu Y; Liu Y; Wang Y; Zhang H
Placenta; 2014 Oct; 35(10):824-30. PubMed ID: 25108485
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Rothschild SI; Gautschi O; Batliner J; Gugger M; Fey MF; Tschan MP
Lung Cancer; 2017 May; 107():73-83. PubMed ID: 27372519
[TBL] [Abstract][Full Text] [Related]
13. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Arcaroli JJ; Quackenbush KS; Powell RW; Pitts TM; Spreafico A; Varella-Garcia M; Bemis L; Tan AC; Reinemann JM; Touban BM; Dasari A; Eckhardt SG; Messersmith WA
Clin Cancer Res; 2012 May; 18(9):2704-14. PubMed ID: 22553375
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers.
Kim JA; Tan Y; Wang X; Cao X; Veeraraghavan J; Liang Y; Edwards DP; Huang S; Pan X; Li K; Schiff R; Wang XS
Nat Commun; 2016 Oct; 7():12991. PubMed ID: 27694828
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Dong M; Rice L; Lepler S; Pampo C; Siemann DW
Anticancer Res; 2010 Nov; 30(11):4405-13. PubMed ID: 21115886
[TBL] [Abstract][Full Text] [Related]
17. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
[TBL] [Abstract][Full Text] [Related]
18. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
19. Activation of membrane progesterone receptor-alpha increases proliferation, migration, and invasion of human glioblastoma cells.
González-Orozco JC; Hansberg-Pastor V; Valadez-Cosmes P; Nicolas-Ortega W; Bastida-Beristain Y; Fuente-Granada M; González-Arenas A; Camacho-Arroyo I
Mol Cell Endocrinol; 2018 Dec; 477():81-89. PubMed ID: 29894708
[TBL] [Abstract][Full Text] [Related]
20. Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.
Calgani A; Vignaroli G; Zamperini C; Coniglio F; Festuccia C; Di Cesare E; Gravina GL; Mattei C; Vitale F; Schenone S; Botta M; Angelucci A
Mol Cancer Ther; 2016 Jul; 15(7):1535-44. PubMed ID: 27196762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
